Max Benzaquen, MD
Neurology · Chesterfield, MONPI 1366426900
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 30.2% of the total. Reporting peaked in 2021 at $27,654 and has fallen 72.2% since, to $7,677 in 2025. Among neurology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,112 payments — averaging $33.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Lilly USA, LLC$8K
- Biohaven Pharmaceuticals, Inc.$7K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Jazz Pharmaceuticals Inc.$4K
- Teva Pharmaceuticals USA, Inc.$3K
- plus $46K from 54 others
Across 62 payments — averaging $3073.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$185K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
What the payments were for
- Consulting fees$10,65310%
- Speaking & faculty fees$34,45733%
- Travel & lodging$3,7334%
- Food & beverage$55,60153%
- Education$7361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,180 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 43 | $349,287 |
| EpidiolexCannabidiol (Cbd) | 26 | $119,538 |
| VraylarCariprazine Hcl | 14 | $38,293 |
| BriviactBrivaracetam | 23 | $35,854 |
| XcopriCenobamate | 24 | $34,596 |
| UbrelvyUbrogepant | 21 | $31,967 |
| QuliptaAtogepant | 23 | $25,666 |
| Nurtec OdtRimegepant Sulfate | 18 | $24,606 |
| NamzaricMemantine Hcl/Donepezil Hcl | 22 | $22,651 |
| BotoxOnabotulinumtoxina | 19 | $20,047 |
| Memantine Hcl ErMemantine Hcl | 182 | $17,388 |
| TrintellixVortioxetine Hydrobromide | 20 | $9,732 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 289 | $8,982 |
| Lacosamide | 49 | $7,266 |
| Carbamazepine ErCarbamazepine | 43 | $6,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $370 | $349,28743 claims |
| AbbVieVraylar, Ubrelvy, Qulipta, Namzaric, Botox | $31,815 | $138,62399 claims |
| UCB, Inc.Briviact | $2,106 | $35,85423 claims |
| SK Life Science, Inc.Xcopri | $2,527 | $34,59624 claims |
| PfizerNurtec Odt | $1,170 | $24,60618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $601 | $9,73220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 neurology providers in Missouri.
Other neurology in Chesterfield
- William RosenfeldChesterfield$2.1M
- Barbara GreenChesterfield$352K
- Emily EvansChesterfield$60K
- Zaheer AhmedChesterfield$20K
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.